Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study

Fig. 1

The overall survival in the eribulin and non-eribulin groups (A), eribulin group of patients who received eribulin at an early line (first or second) and non-eribulin group (B) and eribulin group of patients who received eribulin at a late line (third or later) and non-eribulin group (C). CI: confidence interval, OS: Overall survival

Back to article page